A double-blind, placebo-controlled, dose-ranging study to investigate the safety and efficacy of CY 208-243 in patients with Parkinson's disease.

Abstract

We carried out a double-blind rising dose study of a D-1 dopamine agonist, CY 208-243, in 6 parkinsonian patients. Deficits monitored by Columbia scores were significantly improved at single doses ranging from 5 to 40 mg, though efficacy was low. Used alone, CY 208-243 was not a satisfactory therapeutic agent, and toxicity data precluded further increases in dosage.

• Authors: J K Tsui, E C Wolters, R F Peppard, D B Calne
• Journal: Neurology (Neurology) Vol. 39 Issue 6 Pg. 856-8 (Jun 1989) ISSN: 0028-3878 [Print] United States
• PMID: 2725884 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)

Chemical References

• Indoles
• Phenanthridines
• Placebos
• CY 208-243

Topics

• Dose-Response Relationship, Drug
• Double-Blind Method
• Female
• Humans
• Indoles (adverse effects, therapeutic use)
• Male
• Middle Aged
• Parkinson Disease (drug therapy, physiopathology)
• Phenanthridines (adverse effects, therapeutic use)
• Placebos